CRM vs PFE: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Salesforce, Inc. · Technology
$182.14
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
PFE |
| Current Price |
$182.14 |
$26.33 |
| Fair Value Estimate |
$264.10 |
$33.85 |
| Upside to Fair Value |
+45.0%
|
+28.6%
|
| Market Cap |
$173.0B |
$149.8B |
| Forward P/E |
22.8x
|
19.3x
|
| EV / EBITDA |
14.4x
|
12.9x
|
| Price / Sales |
4.2x
|
2.4x
|
| Price / FCF |
12.0x
|
16.5x
|
| Revenue Growth YoY |
+12.1%
|
-1.2%
|
| Gross Margin |
77.7%
|
70.3%
|
| Operating Margin |
21.5%
|
24.7%
|
| Return on Equity |
12.4%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
8.33%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025. Salesforce exhibi…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
CRM |
PFE |
| Zone Low |
$198.08 |
$25.39 |
| Zone High |
$224.49 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|